Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?
Higher plasma concentrations of tyrosine kinase inhibitors (TKI), such as pazopanib, are associated with improved clinical outcomes. However, TKI pharmacokinetics exhibit significant interpatient variability, resulting in inconsistent and unpredictable plasma drug levels. An individualized dosing approach based on patient pharmacokinetics data and toxicity can potentially optimize plasma concentrations of pazopanib. Clin Cancer Res; 22(23); 5626-8. ©2016 AACRSee related article by Verheijen et al., p. 5738.
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Moshe C
MC
Ornstein
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio. rinib2@ccf.org.
Brian I
BI
Rini
D000284:Administration, Oral; D019540:Area Under Curve; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D004364:Pharmaceutical Preparations; D047428:Protein Kinase Inhibitors